Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453786 | 0.95 | ALDH1A1 (0.53) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL30662328 | 0.94 | MME (0.56) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL29788251 | 0.94 | MME (0.56) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL30112733 | 0.93 | MME (0.61) | MMEALDH1A1BACE1 | |
| SCHEMBL29725304 | 0.92 | MME (0.55) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL3777970 | 0.92 | ALDH1A1 (0.56) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL3777968 | 0.92 | ALDH1A1 (0.56) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL30676222 | 0.92 | ALDH1A1 (0.56) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL30974205 | 0.90 | MME (0.47) | MMEALDH1A1LAP3MEN1LMNA | |
| SCHEMBL29939666 | 0.90 | ACE (0.50) | MMEALDH1A1LAP3MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388954-A1 | PRIMERS WITH SELF-COMPLEMENTARY SEQUENCES FOR MULTIPLE DISPLACEMENT AMPLIFICATION | QIAGEN SCIENCES LLC (US) | 2025-12-25 | — | — | US | claimed |
| EP-4648821-A1 | AN INFUSION SET AND AN ADHESIVE STRUCTURE THEREFOR | Unomedical A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| US-12371740-B2 | Primers with self-complementary sequences for multiple displacement amplification | QIAGEN SCIENCES, LLC (US) | 2025-07-29 | — | — | US | claimed |
| CN-119684428-A | Modulation of yc-cytokine activity | 比奥尼斯治疗公司 | 2025-03-25 | — | — | CN | claimed |
| CN-118846138-A | Compositions comprising fluorophore-labeled uPAR targeting peptide conjugates | 荧光向导股份公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2024149874-A1 | AN INFUSION SET AND AN ADHESIVE STRUCTURE THEREFOR | UNOMEDICAL A/S (DK) | 2024-07-18 | — | — | WO | claimed |
| CN-118256983-A | Preparation method of high-purity mullite whisker based on S-L-S growth mechanism | 中国民航大学 | 2024-06-28 | — | — | CN | claimed |
| CN-115895211-A | Preparation method of antioxidant polyester optical film | 宁波东旭成新材料科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20230060637-A1 | MODULATING GAMMA-C-CYTOKINE ACTIVITY | Bioniz Therapeutics, Inc. | 2023-03-02 | — | — | US | claimed |
| US-11401548-B2 | Primers with self-complementary sequences for multiple displacement amplification | QIAGEN SCIENCES, LLC (US) | 2022-08-02 | — | — | US | claimed |
| US-11400134-B2 | Modulating gamma-c-cytokine activity | BIONIZ, LLC (US) | 2022-08-02 | — | — | US | claimed |
| EP-3998351-A1 | PRIMERS WITH SELF-COMPLEMENTARY SEQUENCES FOR MULTIPLE DISPLACEMENT AMPLIFICATION | Qiagen Sciences, LLC (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3978512-A1 | MODULATING GAMMA-C-CYTOKINE ACTIVITY | Bioniz, LLC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-4736080-A2 | ADJUSTING TUNNEL JUNCTION CHARACTERISTICS OF ATOMIC LAYER DEPOSITION FILMS THROUGH UNDERLAYER MODIFICATION | The Research Foundation for the State University of New York (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12617872-B2 | Heterodimeric human IgG1 polypeptides with isoelectric point modifications | XENCOR, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | Bioniz Therapeutics, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3978512-A1 | MODULATING GAMMA-C-CYTOKINE ACTIVITY | Bioniz, LLC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220090069-A1 | OLIGONUCLEOTIDES FOR HTT-1A MODULATION | UNIV MASSACHUSETTS (US) | 2022-03-24 | — | — | US | disclosed |
| US-11279930-B2 | O-methyl rich fully stabilized oligonucleotides | UNIVERSITY OF MASSACHUSETTS (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3966328-A2 | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS | University Of Massachusetts (US) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220090069-A1 | OLIGONUCLEOTIDES FOR HTT-1A MODULATION | HTT, TARDBP, SNCA | MME 964/4885ALDH1A1 4283/4885LAP3 3344/4885 |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | IL15, IL2, IL15RA | MME 2936/4885ALDH1A1 3007/4885LAP3 3234/4885 |
| US-20250388954-A1 | PRIMERS WITH SELF-COMPLEMENTARY SEQUENCES FOR MULTIPLE DISPLACEMENT AMPLIFICATION | POLL, POLM, POLRMT | MME 2420/4885ALDH1A1 3236/4885LAP3 272/4885 |
| US-12617872-B2 | Heterodimeric human IgG1 polypeptides with isoelectric point modifications | IGLV6-57, CHAMP1, FCGRT | MME 2095/4885ALDH1A1 4514/4885LAP3 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.